


Systems Biology of Cancer

Edited by **Sam Thiagalingam**




Systems Biology of Cancer

Edited by

Sam Thiagalingam

Boston University School of Medicine



CAMBRIDGE
UNIVERSITY PRESS

CAMBRIDGE
UNIVERSITY PRESS

University Printing House, Cambridge CB2 8BS, United Kingdom

Cambridge University Press is part of the University of Cambridge.

It furthers the University's mission by disseminating knowledge in the pursuit of education, learning and research at the highest international levels of excellence.

www.cambridge.org

Information on this title: www.cambridge.org/9780521493390

© Cambridge University Press 2015

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2015

Printed in the United Kingdom by T J International Ltd.
Padstow Cornwall

A catalogue record for this publication is available from the British Library

Library of Congress Cataloguing in Publication data

ISBN 978-0-521-49339-0 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet websites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

.....

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.

Systems Biology of Cancer

With over 200 types of cancer diagnosed to date, researchers the world over have been forced to rapidly update their understanding of the biology of cancer. In fact, only the study of the basic cellular processes, and how these are altered in cancer cells, can ultimately provide a background for rational therapies.

Bringing together the state-of-the-art contributions of international experts, *Systems Biology of Cancer* proposes an ultimate research goal for the whole scientific community: exploiting systems biology to generate in-depth knowledge based on blueprints that are unique to each type of cancer.

Readers are provided with a realistic view of what is known and what is yet to be uncovered on the aberrations in the fundamental biological processes, deregulation of major signaling networks, alterations in major cancers, and the strategies for using the scientific knowledge for effective diagnosis, prognosis, and drug discovery to improve public health.

Sam Thiagalingam is an Associate Professor of Genetics & Genomics, Medicine, and Pathology & Laboratory Medicine at the Boston University School of Medicine. He played a major role in establishing an association between genomic instability and loss of heterozygosity (LOH) in human cancers. He was the first to show that SMAD4 inactivation is a critical event during the late stages of colon cancer progression, and sustained TGF β signaling events are required to maintain epigenetic memory during breast cancer progression. Dr. Thiagalingam also proposed a simple minded multi-modular molecular network (MMMN) cancer progression model as a road map to visualize the various gene alterations in modules of networks of pathways. His long-term goal is to identify novel cancer biomarkers and therapeutic targets by contributing to the “big picture” of interconnected networks of events that mediate cancer progression to metastasis using breast and colon cancers as the model systems.

To my parents

Vanniyan Sambunathan Seenithamby Sisupalapillai Sambasivamoorthy

and

Paramsothy Thangaretnaammal Malar Eliyathamby Sambasivamoorthy

for their righteous living and the respect for freedom of expression.

Contributors

Hamid M. Abdolmaleky

Biomedical Genetics
Boston University School of Medicine and
Nutrition/Metabolism Laboratory
Harvard Medical School
Boston, MA
USA

Cory Adamson

Department of Surgery – Neurosurgery
Duke University School of Medicine
Durham, NC
USA

Paola Allavena

Department of Inflammation and Immunology,
Humanitas Clinical and Research Center
Rozzano
Italy

Dimitrios Anastasiou

Division of Physiology and Metabolism
MRC National Institute for Medical Research
The Ridgeway, Mill Hill
London
UK

Johanna Apfel

Molecular Biology
Biotechnology and Biochemistry Group
University of Applied Sciences
Kaiserslautern
Germany

Surinder K. Batra

Department of Biochemistry and Molecular Biology
Eppley Cancer Institute
University of Nebraska Medical Center
Omaha, NE
USA

Mark E. Burkard

Department of Medicine – Hematology/Oncology
University of Wisconsin
Madison, WI
USA

Amancio Carnero

Instituto de Biomedicina de Sevilla
HUVR/Universidad de Sevilla/Consejo
Superior de Investigaciones Cientificas
Sevilla
Spain

Michael J. Clemens

Department of Biochemistry and Molecular Biology
School of Life Sciences
University of Sussex
Brighton
UK

Jeanette Gowen Cook

Department of Biochemistry & Biophysics
University of North Carolina School of Medicine
Chapel Hill, NC
USA

Isabel Dominguez

Hematology-Oncology Section
Department of Medicine
Boston University School of Medicine
Boston, MA
USA

Jeremy S. Edwards

Molecular Genetics and Microbiology
University of New Mexico School of Medicine and
Chemical and Nuclear Engineering
University of New Mexico
Albuquerque, NM
USA

Wafik S. El-Deiry

Fox Chase Cancer Center
Philadelphia, PA
USA

Androulla Elia

Biomedical Sciences
St. George's University of London
London
UK

Mohammad R. Eskandari

Nutrition/Metabolism Laboratory
Harvard Medical School
Boston, MA
USA

Aurora Esquela-Kerscher

Department of Microbiology & Molecular Cell
Biology
Leroy T. Canoles Jr. Cancer Research Center
Eastern Virginia Medical School
Norfolk, VA
USA

Manel Esteller

Cancer Epigenetics and Biology Program (PEBC)
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)
Barcelona, Catalonia
Spain

Rob M. Ewing

Centre for Biological Sciences
University of Southampton
Southampton
UK

Douglas V. Faller

Cancer Center
Boston University School of Medicine
Boston, MA
USA

Kristopher Frese

Cancer Research UK Cambridge Institute
University of Cambridge
Cambridge
UK

Xijin Ge

Department of Mathematics and Statistics
South Dakota State University
Department of Mathematics and Statistics

Brookings, SD
USA

Giovanni Germano

Department of Inflammation and Immunology
Humanitas Clinical and Research Center
Rozzano
Italy

Daniel A. Haber

Massachusetts General Hospital Cancer Center
Harvard Medical School
Charlestown, MA
USA

William C. Hahn

Department of Medical Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA
USA

Antoine Ho

Molecular Genetics and Microbiology
University of New Mexico School of
Medicine
Albuquerque, NM
USA

Christine Iacobuzio-Donahue

Department of Pathology
Johns Hopkins Sidney Kimmel Comprehensive
Cancer Center
Baltimore, MD
USA

Sergii Ivakhno

Cancer Research UK Cambridge Institute
University of Cambridge
Cambridge
UK

Prasad V. Jallepalli

Molecular Biology Program
Memorial Sloan-Kettering Cancer Center
New York, NY
USA

Rosanne Jones

Department of Pathology
Duke University Medical Center
Durham, NC
USA

Sharyn Katz

Department of Radiology
Hospital of the University of Pennsylvania
Philadelphia, PA
USA

Arnaud Krebs

Functional Genomics Department
Institut de Génétique et de Biologie Moléculaire et
Cellulaire (IGBMC)
Université de Strasbourg (UdS)
Strasbourg
France

Karl Krueger

Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute
Rockville, MD
USA

Arthur W. Lambert

Whitehead Institute for Biomedical Research
Massachusetts Institute of Technology
Cambridge, MA
USA

Adam Lerner

Hematology/Oncology Section
Departments of Medicine
Boston University School of Medicine
Boston, MA
USA

Holly Lewis

Department of Microbiology & Molecular Cell Biology
Leroy T. Canoles Jr. Cancer Research Center
Eastern Virginia Medical School
Norfolk, VA
USA

Jason W. Locasale

Division of Nutritional Sciences
Cornell University
Ithaca, NJ
USA

Giselle Y. López

Department of Pathology
University of California, San Francisco
San Francisco, CA
USA

Shyamala Maheswaran

Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, MA
USA

Alberto Mantovani

Department of Inflammation and Immunology
Humanitas Clinical and Research Center
Rozzano
Italy

José Ignacio Martín-Subero

Cancer Epigenetics and Biology Program
(PEBC)
Institut d'Investigació Biomèdica de Bellvitge
(IDIBELL)
Barcelona, Catalonia
Spain

Simon J. Morley

Department of Biochemistry and Molecular Biology
School of Life Sciences
University of Sussex
Brighton
UK

Oliver Müller

Molecular Biology, Biotechnology and Biochemistry
Group
University of Applied Sciences
Kaiserslautern
Germany

Kathleen R. Nevis

Department of Pathology
University of North Carolina School of Medicine
Chapel Hill, NC
USA

Sait Ozturk

Department of Oncological Sciences
Icahn School of Medicine at Mount Sinai
New York, NY
USA

Panagiotis Papageorgis

Departments of Biological Sciences and Mechanical
Engineering
University of Cyprus
Nicosia
Cyprus

Jignesh R. Parikh

Bioinformatics Program
Boston University
Boston, MA
USA

Steven M. Powell

Gastroenterology & Hepatology
University of Virginia School of Medicine
Charlottesville, VA
USA

Kimberly L. Raiford

Department of Biochemistry and Biophysics
University of North Carolina School
of Medicine
Chapel Hill, NC
USA

Andrew M. Rankin

Cancer Center
Boston University School of Medicine
Boston, MA
USA

Patricia Reischmann

Molecular Biology
Biotechnology and Biochemistry Group
University of Applied Sciences
Kaiserslautern
Germany

Simon Rosenfeld

Biometry Research Group
Division of Cancer Prevention
National Cancer Institute
Rockville, MD
USA

Marc Samsky

Department of Pathology
Duke University Medical Center
Durham, NC
USA

Anthony Scott

Department of Genetics
Case Western Reserve University School of
Medicine
Cleveland, OH
USA

Shantibhusan Senapati

Institute of Life Sciences
Bhubaneswar
India

Yashaswi Shrestha

Dana-Farber Cancer Institute
Harvard Medical School and
Broad Institute of Harvard and MIT
Boston, MA
USA

Anurag Singh

Department of Pharmacology and
The Cancer Center
Boston University School of Medicine
Boston, MA
USA

Rakesh K. Singh

Department of Pathology and Microbiology
University of Nebraska Medical Center
Omaha, NE
USA

Gromoslaw A. Smolen

Massachusetts General Hospital Cancer Center
Harvard Medical School
Charlestown, MA
USA

Sudhir Srivastava

Cancer Biomarkers Research Group
Division of Cancer Prevention
National Cancer Institute
Rockville, MD
USA

Simon Tavaré

Cancer Research UK Cambridge Institute
University of Cambridge
Cambridge
UK

Sam Thiagalingam

Biomedical Genetics, Cancer Center
Genetics & Genomics and Pathology & Laboratory
Medicine
Boston University School of Medicine
Boston, MA
USA

László Tora

Functional Genomics Department
Institut de Génétique et de Biologie Moléculaire et
Cellulaire (IGBMC)
Université de Strasbourg (UdS)
Strasbourg
France

David Tuveson

Cancer Research UK Cambridge Research
Institute
University of Cambridge
Cambridge, UK and
Cold Spring Harbor Laboratory
Cold Spring Harbor, NY
USA

Asad Umar

Division of Cancer Prevention
National Cancer Institute
Rockville, MD
USA

Matthew G. Vander Heiden

Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA
USA

Cyrus Vaziri

Department of Pathology and Laboratory
Medicine
University of North Carolina School of
Medicine
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC
USA

Zhenghe John Wang

Department of Genetics
Case Western Reserve University School of
Medicine
Cleveland, OH
USA

Kevin Webster

Cancer Bioscience
AstraZeneca R&D Boston
Waltham, MA
USA

Chen Khuan Wong

Genetics and Genomics
Boston University School of Medicine
Boston, MA
USA

Yu Xia

Department of Bioengineering
McGill University
Montreal, Quebec
Canada

Hai Yan

Department of Pathology
Duke University School of Medicine
Durham, NC
USA

Jian Yu

Department of Pathology
University of Pittsburgh Cancer Institute
University of Pittsburgh School of Medicine
Pittsburgh, PA
USA

Lihua Yu

Cancer Bioscience
AstraZeneca R&D Boston
Waltham, MA
USA

Min Yu

Massachusetts General Hospital Cancer Center
Harvard Medical School
Charlestown, MA
USA

Lin Zhang

Department of Pharmacology
University of Pittsburgh Cancer Institute
University of Pittsburgh School of Medicine
Pittsburgh, PA
USA

Jin-Rong Zhou

Nutrition/Metabolism Laboratory
Beth Israel Deaconess Medical Center
Harvard Medical School
Boston, MA
USA

Preface

The heterogeneity in alterations and the failure to detect consistent changes in a unique set of gene(s) or gene products in similar and histologically well defined neoplasms pose a challenge for the accurate diagnosis, prognosis and therapy of cancer. Consequently, there is a need to integrate the individual observations made in tumor cells derived from numerous sources using the systems biology approach to identify a panel of alternate target genes/gene products as biomarkers for diagnosis and/or prognosis and as targets for therapy. This goal could be achieved with efficacy by dissecting alterations in cancer in interconnected modular networks of pathways represented in multi-modular molecular networks (MMMN) specific for progression of individual cancers. This landmark volume consisting of a collection of chapters examines the fundamentals of the molecular basis of the genesis of cancer in parts devoted to the overall big picture, basic biochemical events, manifestation of fingerprints of alterations, units of coordinated events, state of knowledge of the integrated progression of events for specific cancers and the future prospects and implications of the various MMMN cancer progression models in the fight against cancer.

My sincere thanks to the distinguished scientists for graciously contributing chapters on their expertise. My special gratitude to my doctoral thesis advisor, Professor Lawrence Grossman, for his guidance in shaping up my career as a molecular biologist and for stimulating my passion to undertake cancer research as the next step to studying DNA repair

mechanisms, and to my post-doctoral advisor, Professor Bert Vogelstein, for being a role model and for sharing his wealth of knowledge and expertise in the field of cancer genetics and biology. My special appreciation to Allan Ross (Former Executive Editor, Medicine and Life Sciences, Cambridge University Press, New York) for inviting me to conceive this volume and for all his assistance at the initial stages of the development of this volume. I am indebted to my students, Arthur Lambert and Chen Wong for critical comments and proofreading and Panagiotis Papa-georgis and Sait Ozturk for help with illustrations. I am thankful to Ilaria Tassistro (Assistant Editor, Life Sciences, Cambridge University Press, Cambridge, UK) and Katrina Halliday (Editor and Publisher, Life Sciences, Cambridge University Press, Cambridge, UK) for their patience with the last minute delays and guidance and Kath Pilgrem (Copy Editor) and Jessica Ann Murphy (Production Editor Academic Books, Cambridge University Press, Cambridge, UK) for their help with finalizing this volume for publication. On behalf of the authors, I would also like to thank the American Association for Cancer Research, Nature Publishing Group, Wolters Kluwer Health, and others for allowing partial or full reproduction of their previously published figures.

This project would not have been completed without the encouragement, support and the enduring love of my wife Arunthathi Cumaraswamy Thiagalingam and the unconditional love of my children Natasha Thivya Thiagalingam and Aaron Gajan Thiagalingam.

Contents

List of contributors ix

Preface xv

Part 1 – Introduction to modular organization of the networks of gene functions and cancer

- 1 **Systems biology of cancer progression** 1
Sam Thiagalingam
- 2 **Lessons from cancer genome sequencing** 7
Antoine Ho and Jeremy S. Edwards
- 3 **Application of bioinformatics to analyze the expression of tissue-specific and housekeeping genes in cancer** 20
Xijin Ge

Part 2 – Alterations in the regulatory networks of cellular and molecular events

- 4 **Events at DNA replication origins and genome stability** 35
Kathleen R. Nevis, Kimberly L. Raiford, Cyrus Vaziri and Jeanette Gowen Cook
- 5 **Systems biology approaches bring new insights in the understanding of global gene regulatory mechanisms and their deregulation in cancer** 56
Arnaud Krebs and László Tora
- 6 **Regulation and dysregulation of protein synthesis in cancer cells** 70
Michael J. Clemens, Androulla Elia and Simon J. Morley

Part 3 – Events responsible for aberrant genetic and epigenetic codes in cancer

- 7 **Genomic instability and carcinogenesis** 93
Mark E. Burkard and Prasad V. Jallepalli
- 8 **Epigenomic code** 113
José Ignacio Martín-Subero and Manel Esteller
- 9 **MicroRNA epigenetic systems and cancer** 134
Holly Lewis and Aurora Esquela-Kerscher
- 10 **Dietary and environmental influences on the genomic and epigenomic codes in cancer** 154
Hamid M. Abdolmaleky, Mohammad R. Eskandari and Jin-Rong Zhou

Part 4 – Functional networks of events that modulate phenotypic manifestation of cancer

- 11 **Regulatory signaling networks in cell transformation and cancer** 169
Yashaswi Shrestha and William C. Hahn
- 12 **RAS signaling networks** 183
Douglas V. Faller and Andrew M. Rankin
- 13 **PI3K pathway in cancer** 193
Amancio Carnero
- 14 **TGF β and BMP signaling in cancer** 204
Panagiotis Papageorgis, Arthur W. Lambert, Sait Ozturk and Sam Thiagalingam

- 15 **The Wnt signaling network in cancer** 222
Johanna Apfel, Jignesh R. Parikh, Patricia Reischmann, Rob M. Ewing, Oliver Müller, Yu Xia and Isabel Dominguez
- 16 **Apoptotic pathways and cancer** 256
Jian Yu and Lin Zhang
- 17 **Molecular links between inflammation and cancer** 273
Paola Allavena, Giovanni Germano and Alberto Mantovani
- 18 **Cancer metastasis** 282
Sait Ozturk, Arthur W. Lambert, Chen Khuan Wong, Panagiotis Papageorgis and Sam Thiagalingam
- 19 **Cancer metabolism** 295
Dimitrios Anastasiou, Jason W. Locasale and Matthew G. Vander Heiden
- 20 **Tumor microenvironment: blood vascular system in cancer metastasis** 309
Shantibhusan Senapati, Rakesh K. Singh and Surinder K. Batra
- Part 5 – Current state of the evolving MMMN cancer progression models of cancer**
- 21 **Genetic alterations in glioblastoma multiforme** 323
Giselle Y. López, Marc Samsky, Rosanne Jones, Cory Adamson and Hai Yan
- 22 **Breast cancer** 345
Arthur W. Lambert, Sait Ozturk, Chen Khuan Wong, Panagiotis Papageorgis and Sam Thiagalingam
- 23 **The role of growth factor-induced changes in cell fate in prostate cancer progression** 361
Min Yu, Gromoslaw A. Smolen, Daniel A. Haber and Shyamala Maheswaran
- 24 **Colon cancer** 377
Anthony Scott and Zhenghe John Wang
- 25 **Biology of human stomach cancer** 386
Bryan G. Sauer and Steven M. Powell
- 26 **Pancreatic cancer** 409
Sergii Ivakhno, Kristopher Frese, Simon Tavaré, Christine Iacobuzio-Donahue and David Tuveson
- 27 **Deregulated signaling networks in lung cancer** 421
Anurag Singh
- 28 **Modular signaling in hematopoietic malignancies** 443
Adam Lerner
- Part 6 – Applications of comprehensive cancer progression models in the fight against cancer**
- 29 **Role of network biology and network medicine in early detection of cancer** 457
Asad Umar and Simon Rosenfeld
- 30 **Systems biology in cancer biomarkers for early detection, diagnosis, and prognosis** 464
Sudhir Srivastava and Karl Krueger
- 31 **Prognosis of cancer** 473
Sharyn Katz and Wafik S. El-Deiry
- 32 **Cancer pharmacogenomics: challenges, promises, and its application to cancer drug discovery** 499
Lihua Yu and Kevin Webster
-
- Index* 518
-
- The color plate section appears between pages 320 and 321.*